Latest News
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan
3 June 2026 - Luminopia Inc, a digital health company developing a new class of treatments for neuro-visual disorders, announced on Tuesday its first international licensing agreement with ROHTO Pharmaceutical Co LTD, a Japanese multinational corpora...
Cumberland Pharmaceuticals and Vanderbilt Health report data from Phase 2a trial of ifetroban to prevent cancer metastasis
3 June 2026 - Specialty pharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq:CPIX) and healthcare provider Vanderbilt Health on Tuesday announced data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumou...
Creatv Bio partners with Neovia Oncology to study multiple drug resistance in solid tumours
3 June 2026 - Creatv Bio, a division of Creatv MicroTech Inc, a liquid biopsy company focused on innovative diagnostics for cancer, and Neovia Oncology LLC, a pharmaceutical company developing novel oncology therapies, announced on Tuesday the signin...
First Foundation Labs partners with Microsoft to bring AI-powered clinical and translational reasoning to Microsoft Discovery
3 June 2026 - First Foundation Labs (1FL), a life sciences AI company spun out of Luma Group, announced on Tuesday a collaboration with Microsoft (NASDAQ:MSFT) to accelerate the development and enterprise deployment of its reasoning platform through ...
FDA accepts Genentech's giredestrant application for early-stage breast cancer
2 June 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Tuesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application under Priority Review for giredestrant as a...